Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems to Ditch Rx Business, Focus on Dx

NEW YORK (GenomeWeb News) – Proteome Systems today said that it would shut down its drug development business and focus solely on biomarker-based diagnostics operations.
 
The Sydney, Australia-based firm has been trying to develop a therapeutic compound portfolio since its merger with Eukarion in 2005. However, that portfolio “no longer fits with our corporate development strategy,” the company said.
 
Proteome said it will continue research via funding from the US government but will close its Boston office within the next three months. It said that it will retain the rights to a portfolio of assets covering antioxidant compounds for dermatological and neurological indications, and it will consider out-licensing opportunities.
 
The firm expects the closure of its US operations to save $550,000 per year starting in February 2009.
 
Proteome said it will focus on its near-term revenue-generating programs, particularly a collaboration with Bayer CropSciences for its WheatRite test for wheat quality and a partnership with Becton Dickinson for a tuberculosis test.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.